Overcoming Deadly Diseases

Imipridones

A new class of cancer therapies

Improving and Extending Lives

Chimerix’s mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases.  Learn more about our approach to investing in novel drug candidates that meaningfully improve the probability of survival and the collaborative team driving the development of these promising new therapies.

TEMBEXA® Transaction

Chimerix Announces Sale of TEMBEXA to Emergent BioSolutions for up $238 Million Up Front Plus Additional $136.5 Million in Potential Milestones Plus Royalties.

More about TEMBEXA® Transaction

2022 Society of Neuro-Oncology Annual Meeting

Come see us at the 2022 SNO Meeting Nov 17-19 in Tampa, FL. Our full team will be onsite to discuss ONC201, the  ACTION study and advances in the treatment of glioma.

SNO 2022 Details

NEWS

view all